Physician profile
Keith Eric Goulet
NPI 1831154079
$8,075.18
in general payments reported to CMS, 2019-2025
34 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $42.16 · 2021: $983 · 2022: $1,309 · 2023: $1,653 · 2024: $1,462 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,669 · Education: $84.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,669.31 |
| Education | $84.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,964.01 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,073.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $903.86 | 2019-2024 | Ofev, Stiolto Respimat |
| Grifols USA, LLC | $709.08 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $470.20 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $442.19 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $322.66 | 2019-2024 | Xolair |
| Actelion Pharmaceuticals US, INC. | $209.39 | 2019-2024 | Opsumit, Uptravi |
| Insmed, INC. | $197.25 | 2019-2025 | Brinsupri, Arikayce |
| Amgen INC. | $197.03 | 2021-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $174.54 | 2019-2024 | |
| Viatris Specialty LLC | $167.67 | 2025 | Yupelri |
| Electromed, INC. | $166.56 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $144.31 | 2025 | Ohtuvayre |
| Pharming Healthcare, INC. | $130.98 | 2023 | Ruconest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $102.70 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.61 | 2021-2024 | Glassia |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Merck Sharp & Dohme LLC | $65.54 | 2024-2025 | Zerbaxa |
| Philips North America LLC | $59.64 | 2021-2023 | |
| Inogen, INC. | $57.78 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| United Therapeutics Corporation | $50.46 | 2022-2023 | Tyvaso |
| Sunovion Pharmaceuticals INC. | $48.03 | 2019 | |
| Paratek Pharmaceuticals, INC. | $32.56 | 2022 | |
| Gilead Sciences, INC. | $30.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.13 | 2021 | |
| Advanced Respiratory, INC | $25.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.40 | 2024 | Xarelto |
| Baxter Healthcare | $19.75 | 2023 | Hillrom - Life 2000 Ventilation System |
| Pfizer INC. | $18.21 | 2024 | |
| Shire North American Group INC | $17.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.22 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.11 | 2021 | |
| Circassia INC. | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Goulet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.